van Oers JAH, Kluiters Y, Bons JAP, et al. - This study was undertaken to investigate the ability of mid-regional proadrenomedullin (MR-proADM) and C-terminal proendothelin-1 (CT-proET-1) to predict 28-day mortality in critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Researchers collected biomarkers during the first seven days in this prospective observational cohort study. The association between biomarkers and mortality was evaluated in a multivariable Cox regression model adjusted for age and SOFA score. It was shown that 28-day mortality was 28.6% in 105 critically ill patients with confirmed SARS-CoV-2 pneumonia. The results showed that in critically ill patients with SARS-CoV-2 pneumonia, baseline and serial MR-proADM and CT-proET-1 had a good ability to predict 28-day mortality.